Literature DB >> 27124800

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Chadi Nabhan1, Xiaolei Zhou2, Bann-Mo Day3, Keith Dawson3, Andrew D Zelenetz4, Jonathan W Friedberg5, James R Cerhan6, Brian K Link7, Christopher R Flowers8.   

Abstract

We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72-0.97). Lymphoma-related mortality (HR, 0.46; 0.23-0.93) and overall survival (HR, 0.63; 0.41-0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770-775, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27124800      PMCID： PMC5564298          DOI： 10.1002/ajh.24401

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  20 in total

1.  Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.

Authors:  Chadi Nabhan; Michelle Byrtek; Michael D Taylor; Jonathan W Friedberg; James R Cerhan; John D Hainsworth; Thomas P Miller; Jamie Hirata; Brian K Link; Christopher R Flowers
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

2.  Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.

Authors:  H R Junlén; S Peterson; E Kimby; S Lockmer; O Lindén; H Nilsson-Ehle; M Erlanson; H Hagberg; A Rådlund; O Hagberg; B E Wahlin
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

3.  Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2014-08

4.  Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012.

Authors:  Raymond Boon Tar Lim; En Yun Loy; Gek Hsiang Lim; Huili Zheng; Khuan Yew Chow; Soon Thye Lim
Journal:  Int J Cancer       Date:  2015-06-25       Impact factor: 7.396

5.  Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

Authors:  M Federico; U Vitolo; P L Zinzani; T Chisesi; V Clò; G Bellesi; M Magagnoli; M Liberati; C Boccomini; P Niscola; V Pavone; A Cuneo; G Santini; M Brugiatelli; L Baldini; L Rigacci; L Resegotti
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

6.  Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan.

Authors:  Katsuyoshi Takata; Hiroyuki Okada; Naoki Ohmiya; Shotaro Nakamura; Yasuhiko Kitadai; Akira Tari; Taiji Akamatsu; Hiroki Kawai; Shu Tanaka; Hiroshi Araki; Takashi Yoshida; Hirokazu Okumura; Hogara Nishisaki; Tamotsu Sagawa; Norihiko Watanabe; Nobuyoshi Arima; Noritaka Takatsu; Masanao Nakamura; Shunichi Yanai; Hiroyasu Kaya; Toshiaki Morito; Yasuharu Sato; Hisataka Moriwaki; Choitsu Sakamoto; Yasumasa Niwa; Hidemi Goto; Tsutomu Chiba; Takayuki Matsumoto; Daisuke Ennishi; Tomohiro Kinoshita; Tadashi Yoshino
Journal:  Cancer Sci       Date:  2011-06-15       Impact factor: 6.716

7.  Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Authors:  Michael Pfreundschuh; Viola Poeschel; Samira Zeynalova; Mathias Hänel; Gerhard Held; Norbert Schmitz; Andreas Viardot; Martin H Dreyling; Michael Hallek; Carsten Mueller; Martin H J Wiesen; Mathias Witzens-Harig; Lorenz Truemper; Ulrich Keller; Tanja Rixecker; Carsten Zwick; Niels Murawski
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

10.  The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.

Authors:  Loretta J Nastoupil; Rajni Sinha; Michelle Byrtek; Xiaolei Zhou; Michael D Taylor; Jonathan W Friedberg; Brian K Link; James R Cerhan; Keith Dawson; Christopher R Flowers
Journal:  Cancer       Date:  2014-03-25       Impact factor: 6.860
View more
  9 in total

1.  Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.

Authors:  Andrew J Ritter; Jordan S Goldstein; Amy A Ayers; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-01-11

2.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Authors:  Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles
Journal:  J Clin Oncol       Date:  2018-11-27       Impact factor: 44.544

3.  Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.

Authors:  Melody Becnel; Christopher R Flowers; Loretta J Nastoupil
Journal:  Ann Lymphoma       Date:  2017-11-17

4.  Perceptions of clinical care and research among African-American patients with lymphoma.

Authors:  Kaylin V Dance; Conner B Imbody; Lillian Chen; Lorna McNeill; Jackelyn B Payne; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2021-02-28

5.  Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Authors:  S I Tracy; M J Maurer; T E Witzig; M T Drake; S M Ansell; G S Nowakowski; C A Thompson; D J Inwards; P B Johnston; I N Micallef; C Allmer; W R Macon; G J Weiner; S L Slager; T M Habermann; B K Link; J R Cerhan
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

Review 6.  Our Environment Shapes Us: The Importance of Environment and Sex Differences in Regulation of Autoantibody Production.

Authors:  Michael Edwards; Rujuan Dai; S Ansar Ahmed
Journal:  Front Immunol       Date:  2018-03-08       Impact factor: 7.561

7.  The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Authors:  Frederick Lansigan; Ian Barak; Brandelyn Pitcher; Sin-Ho Jung; Bruce D Cheson; Myron Czuczman; Peter Martin; Eric Hsi; Heiko Schöder; Scott Smith; Nancy L Bartlett; John P Leonard; Kristie A Blum
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

8.  A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.

Authors:  David Proudman; Dave Nellesen; Deepshekhar Gupta; Deyaa Adib; Jay Yang; Khalid Mamlouk
Journal:  Adv Ther       Date:  2022-02-14       Impact factor: 3.845

9.  Rituximab maintenance therapy of follicular lymphoma in clinical practice.

Authors:  Ulrich Dührsen; Stefanie Broszeit-Luft; Annette Dieing; Andreas Lück; Piotr Porowski; Marcel Reiser; Ulrike Schwinger; Sandra Klawitter; Katja Krumm; Kathleen Jentsch-Ullrich
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.